In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed the day trading at $0.22 up 3.40% from the previous closing price of $0.22. In other words, the price has increased by $3.40 from its previous closing price. On the day, 1.54 million shares were traded. ADAP stock price reached its highest trading level at $0.2408 during the session, while it also had its lowest trading level at $0.2035.
Ratios:
For a better understanding of ADAP, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.92. In the meantime, Its Debt-to-Equity ratio is 6.26 whereas as Long-Term Debt/Eq ratio is at 5.86.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 30, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On May 30, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $3.15.
On March 24, 2023, Bryan Garnier started tracking the stock assigning a Buy rating and target price of $3.60.Bryan Garnier initiated its Buy rating on March 24, 2023, with a $3.60 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 17 ’25 when Norry Elliot sold 5,584 shares for $0.58 per share. The transaction valued at 3,243 led to the insider holds 7,510 shares of the business.
Lunger John sold 5,584 shares of ADAP for $3,243 on Jan 17 ’25. The Chief Patient Supply Officer now owns 7,510 shares after completing the transaction at $0.58 per share. On Jan 17 ’25, another insider, Bertrand William C JR, who serves as the Chief Operating Officer of the company, sold 5,584 shares for $0.58 each. As a result, the insider received 3,243 and left with 7,510 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 57182672 and an Enterprise Value of 265699968. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.32 while its Price-to-Book (P/B) ratio in mrq is 4.80. Its current Enterprise Value per Revenue stands at 1.492 whereas that against EBITDA is -6.452.
Stock Price History:
The Beta on a monthly basis for ADAP is 2.75, which has changed by -0.7885714 over the last 52 weeks, in comparison to a change of 0.059571505 over the same period for the S&P500. Over the past 52 weeks, ADAP has reached a high of $1.48, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is -49.26%, while the 200-Day Moving Average is calculated to be -71.39%.
Shares Statistics:
Over the past 3-months, ADAP traded about 1.69M shares per day on average, while over the past 10 days, ADAP traded about 2805020 shares per day. A total of 255.94M shares are outstanding, with a floating share count of 226.52M. Insiders hold about 11.49% of the company’s shares, while institutions hold 37.35% stake in the company. Shares short for ADAP as of 1743379200 were 5454233 with a Short Ratio of 3.22, compared to 1740700800 on 6358415. Therefore, it implies a Short% of Shares Outstanding of 5454233 and a Short% of Float of 3.17.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
